Physician profile
Ravi Kalhan
NPI 1629017009
$375,113.87
in general payments reported to CMS, 2019-2025
19 companies · $67K in 2025
The $67K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $31K · 2021: $16K · 2022: $60K · 2023: $74K · 2024: $72K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $152K · Consulting Fee: $41K · Travel and Lodging: $15K · Food and Beverage: $4,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $152,145.00 |
| Consulting Fee | $41,360.00 |
| Travel and Lodging | $15,126.89 |
| Food and Beverage | $4,921.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $307,213.19 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $59,457.05 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,295.36 | 2022-2025 | Spiriva Respimat |
| Verona Pharma, INC. | $1,693.15 | 2025 | Ohtuvayre |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $303.44 | 2019-2025 | Dupixent |
| Insmed, INC. | $206.36 | 2019-2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $112.95 | 2019 | |
| Genzyme Corporation | $54.89 | 2022 | |
| Pulmonx Corporation | $53.64 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Merck Sharp & Dohme LLC | $43.41 | 2023 | |
| Amgen INC. | $38.11 | 2022-2024 | Tezspire |
| Inogen, INC. | $28.44 | 2025 | |
| Allergan, INC. | $13.88 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Kalhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.